GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SLS BIO Co Ltd (XKRX:246250) » Definitions » COGS-to-Revenue

SLS BIO Co (XKRX:246250) COGS-to-Revenue : 0.84 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is SLS BIO Co COGS-to-Revenue?

SLS BIO Co's Cost of Goods Sold for the three months ended in Mar. 2025 was ₩1,483 Mil. Its Revenue for the three months ended in Mar. 2025 was ₩1,755 Mil.

SLS BIO Co's COGS to Revenue for the three months ended in Mar. 2025 was 0.84.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. SLS BIO Co's Gross Margin % for the three months ended in Mar. 2025 was 15.51%.


SLS BIO Co COGS-to-Revenue Historical Data

The historical data trend for SLS BIO Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SLS BIO Co COGS-to-Revenue Chart

SLS BIO Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.74 0.74 0.61 0.66 0.73

SLS BIO Co Quarterly Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.64 0.74 0.83 0.84

SLS BIO Co COGS-to-Revenue Calculation

SLS BIO Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=6102.341 / 8371.295
=0.73

SLS BIO Co's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1482.681 / 1754.825
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SLS BIO Co  (XKRX:246250) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

SLS BIO Co's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1482.681 / 1754.825
=15.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


SLS BIO Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of SLS BIO Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SLS BIO Co Business Description

Traded in Other Exchanges
N/A
Address
Gwanggyo Central Biz Tower, 7th floor, Changryong-dong 260, Gyeonggi-do, Suwon-si, KOR, 16229
SLS BIO Co Ltd is engaged in providing drug development supporting services and pharmaceutical product QC through general tests and assays and instrumental analysis.

SLS BIO Co Headlines

No Headlines